Phase 3 Lung Cancer Trial, RecruitingNCT05920356Sponsor: AmgenCondition: Lung Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT05920356 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with a specific type of lung cancer (non-squamous, non-small cell lung cancer) that is at an advanced or late stage (Stage IIIB, IIIC, or Stage IV), confirmed through a laboratory test on a tissue or cell sample.
People whose lung cancer has a specific genetic change called the KRAS G12C mutation, and whose tumour has tested negative for a protein called PD-L1 (confirmed through central or local laboratory testing).
People who have not previously received any systemic cancer treatment (such as chemotherapy or immunotherapy) for their cancer at its current advanced or incurable stage.
People who are relatively well and able to carry out daily activities, as measured by a standard health scale called the ECOG score of 0 or 1 (confirm with trial site).
Who may not be able to join:
People whose lung cancer contains a mix of cancer cell types, specifically those with a small-cell or large-cell neuroendocrine component, or where the cancer is mainly of the squamous cell type.
People whose tumour has a different genetic change for which a targeted therapy is already locally approved as a first treatment option.
People who have brain metastases (cancer that has spread to the brain) causing symptoms, whether or not those metastases have been treated.
People who have a condition affecting the digestive system that prevents them from swallowing or absorbing oral (by mouth) medication.
People who have had a heart attack within the past 6 months, or who have an unstable irregular heartbeat or unstable chest pain (angina).
People who have previously been treated with a KRAS G12C inhibitor (a specific type of targeted cancer drug).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Campbelltown Hospital, Campbelltown, New South Wales
Concord Repatriation General Hospital, Concord, New South Wales
Nepean Cancer Centre, Kingswood, New South Wales
Port Macquarie Base Hospital, Port Macquarie, New South Wales
GenesisCare -North Shore Oncology, St Leonards, New South Wales
Calvary Mater Newcastle Hospital, Waratah, New South Wales
Toowoomba Hospital, Toowoomba, Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland
Cancer Research South Australia, Adelaide, South Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria
The Alfred Hospital, Melbourne, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05920356
Sponsor: Amgen
Phase: Phase 3
Status: Recruiting
Condition: Lung Cancer
Trial contact: 866-572-6436
More information: https://clinicaltrials.gov/study/NCT05920356
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with a specific type of lung cancer (non-squamous, non-small cell lung cancer) that is at an advanced or late stage (Stage IIIB, IIIC, or Stage IV), confirmed through a laboratory test on a tissue or cell sample.
People whose lung cancer has a specific genetic change called the KRAS G12C mutation, and whose tumour has tested negative for a protein called PD-L1 (confirmed through central or local laboratory testing).
People who have not previously received any systemic cancer treatment (such as chemotherapy or immunotherapy) for their cancer at its current advanced or incurable stage.
People who are relatively well and able to carry out daily activities, as measured by a standard health scale called the ECOG score of 0 or 1 (confirm with trial site).
Who may not be able to join:
People whose lung cancer contains a mix of cancer cell types, specifically those with a small-cell or large-cell neuroendocrine component, or where the cancer is mainly of the squamous cell type.
People whose tumour has a different genetic change for which a targeted therapy is already locally approved as a first treatment option.
People who have brain metastases (cancer that has spread to the brain) causing symptoms, whether or not those metastases have been treated.
People who have a condition affecting the digestive system that prevents them from swallowing or absorbing oral (by mouth) medication.
People who have had a heart attack within the past 6 months, or who have an unstable irregular heartbeat or unstable chest pain (angina).
People who have previously been treated with a KRAS G12C inhibitor (a specific type of targeted cancer drug).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇱 Chile
🇨🇳 China
🇨🇴 Colombia
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
Hong Kong
🇭🇺 Hungary
🇮🇹 Italy
🇯🇵 Japan
🇱🇻 Latvia
🇲🇾 Malaysia
🇲🇽 Mexico
🇳🇱 Netherlands
🇵🇪 Peru
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇷🇴 Romania
🇸🇬 Singapore
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇹🇼 Taiwan
🇹🇭 Thailand
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
11 site(s) in Australia. Confirm current status and contact details directly with the trial site.
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.